Podiatrists in Highlands Ranch, CO Accepting Medicare

6 Podiatrists found. Showing 1 - 6

Mr. William Daniel Farrett Jr., DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 8671 S Quebec St Ste 230, Highlands Ranch, CO 80130 Phone: 303-662-0545    Fax: 720-398-3395

Colorado Clinics For Foot And Ankle Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 9137 Ridgeline Blvd Ste 140, Highlands Ranch, CO 80129 Phone: 303-577-0110    Fax: 303-577-0112

Highlands Foot And Ankle Clinic Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 9331 S Colorado Blvd, Ste. #150, Highlands Ranch, CO 80126 Phone: 303-346-3399

Front Range Podiatry Pllc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1500 Park Central Dr, Highlands Ranch, CO 80129 Phone: 720-662-7184    Fax: 720-662-7616

Mobile Podiatry Group Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 9976 Heatherwood Ln, Highlands Ranch, CO 80126 Phone: 978-886-7780

Christopher Sullivan, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 9976 Heatherwood Ln, Highlands Ranch, CO 80126 Phone: 978-886-7780

News Archive

Rates of cardiovascular disease increase in Australian winters: Seasonal researcher

Rates of cardiovascular disease increase dramatically in Australian winters because many people don't know how to rug up against the cold, a Queensland University of Technology seasonal researcher has found.

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

Antipsychotic drugs increase risk of developing pneumonia in elderly

Elderly patients who use antipsychotic drugs have a 60 percent increased risk of developing pneumonia compared to non-users.

Read more Medical News

› Verified 9 days ago